Compare
Jyong Biotech Ltd. vs Incannex Healthcare Inc. vs Nexentis Technologies Inc. vs Emmaus Life Sciences, Inc.
| Latest fiscal year | Jyong Biotech Ltd. MENS | Incannex Healthcare Inc. IXHL | Nexentis Technologies Inc. NXTS | Emmaus Life Sciences, Inc. EMMA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $86.0K | n/a | $12.45M |
| Revenue growth (YoY) | n/a | +616.7% | n/a | -25.2% |
| Gross margin | n/a | n/a | n/a | 93.1% |
| Operating margin | n/a | n/m | n/a | 1.9% |
| Net margin | n/a | n/m | n/a | -60.2% |
| Net income | -$4.67M | -$46.88M | -$4.00M | -$7.49M |
| EPS (Diluted) | -$0.06 | -$1.35 | -$8.61 | -$0.12 |
| Operating cash flow | -$3.04M | -$12.51M | -$3.81M | -$11.0K |
| Free cash flow | n/a | -$12.52M | -$3.82M | -$12.0K |
| Cash & equivalents | n/a | $15.04M | $3.83M | $2.13M |
| Total assets | $20.78M | $20.45M | $20.41M | $21.44M |
| Total liabilities | $45.68M | $7.06M | $4.67M | $85.04M |
| Shareholders' equity | -$24.91M | $13.39M | $16.01M | -$63.61M |
| Return on year-end equity | n/a | -350.2% | -25.0% | n/a |
| Shares outstanding | 76.03M | 194.38M | 2.77M | 70.19M |
Revenue, most recent five fiscal years
| Fiscal year | Jyong Biotech Ltd. | Incannex Healthcare Inc. | Nexentis Technologies Inc. | Emmaus Life Sciences, Inc. |
|---|---|---|---|---|
| Latest | n/a | $86.0K Ended 2025-06-30 | $210.0K Ended 2024-12-31 | $12.45M Ended 2025-12-31 |
| 1 year earlier | n/a | $12.0K Ended 2024-06-30 | $263.0K Ended 2023-12-31 | $16.65M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $394.0K Ended 2022-12-31 | $29.60M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $438.1K Ended 2021-12-31 | $18.39M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $232.3K Ended 2020-12-31 | $20.61M Ended 2021-12-31 |